VIR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

19.91M

+60.86%

-0.507

-33.24%

2.37M

-21.87%

-0.613

-30.4%

2.37M

+95.12%

-0.550

-31.25%

Estimates Revision

The market is revising Upward the revenue expectations for Vir Biotechnology, Inc. (VIR) for FY2025, with the revenue forecasts being adjusted by 84.85% over the past three months. During the same period, the stock price has changed by 0.86%.

Revenue Estimates for FY2025

Revise Upward

+84.85%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.99%

In Past 3 Month

Stock Price

Go Up

+0.86%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast VIR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIR is 17.67 USD with a low forecast of 12.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

12.00

Averages

17.67

High

31.00

Current: 0.000

Low

12.00

Averages

17.67

High

31.00

BofA

Buy

downgrade

$14 -> $13

2026-01-06

New

Reason

BofA

Price Target

$14 -> $13

2026-01-06

New

downgrade

Buy

Reason

BofA lowered the firm's price target on Vir Biotechnology to $13 from $14 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Evercore ISI

Outperform

initiated

$12

2025-09-03

Reason

Evercore ISI

Price Target

$12

2025-09-03

initiated

Outperform

Reason

Evercore ISI initiated coverage of Vir Biotechnology with an Outperform rating and $12 price target. The firm sees a \"compelling asymmetric setup\" for the shares. Investors are underappreciating how quickly the Vir story can turn around, the analyst tells investors in a research note. Evercore believes the company has a \"differentiated\" oncology pipeline and pivotal-stage rare disease asset with validated biology. However, the stock trade below its cash position, the firm points out.

BofA

Neutral -> Buy

upgrade

$12 -> $14

2025-08-27

Reason

BofA

Price Target

$12 -> $14

2025-08-27

upgrade

Neutral -> Buy

Reason

BofA upgraded Vir Biotechnology to Buy from Neutral with a price target of $14, up from $12.

BofA

Alec Stranahan

Neutral -> Buy

upgrade

$12 -> $14

2025-08-27

Reason

BofA

Alec Stranahan

Price Target

$12 -> $14

2025-08-27

upgrade

Neutral -> Buy

Reason

As previously reported, BofA analyst Alec Stranahan upgraded Vir Biotechnology to Buy from Neutral with a price target of $14, up from $12, arguing that the market is underestimating the potential for its asset for treatment of severe liver disease caused by hepatitis delta virus. There also seems to be minimal value attributed to T-cell engager oncology programs, despite initial proof-of-concept data, the analyst tells investors.

Raymond James

initiated

$12

2025-07-11

Reason

Raymond James

Price Target

$12

2025-07-11

initiated

Reason

Raymond James initiated coverage of Vir Biotechnology with an Outperform rating and $12 price target.

Raymond James

Sean McCutcheon

Outperform

initiated

$12

2025-07-11

Reason

Raymond James

Sean McCutcheon

Price Target

$12

2025-07-11

initiated

Outperform

Reason

Raymond James analyst Sean McCutcheon initiated coverage of Vir Biotechnology with an Outperform rating and $12 price target. Vir's VIR-5500 shows "compelling" early Phase 1 data in heavily treated metastatic castration-resistant prostate cancer patients, and VIR-5500 is well-positioned to capture share in the large and growing mCRPC market, the analyst tells investors in a research note. The firm's constructive view is balanced by competitive headwinds in prostate cancer, as well as the company's high burn rate and need for additional financing to bring VIR-5500 through pivotal studies.

Valuation Metrics

The current forward P/E ratio for Vir Biotechnology Inc (VIR.O) is -2.69, compared to its 5-year average forward P/E of -6.18. For a more detailed relative valuation and DCF analysis to assess Vir Biotechnology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.18

Current PE

-2.69

Overvalued PE

10.51

Undervalued PE

-22.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.58

Current EV/EBITDA

-1.06

Overvalued EV/EBITDA

9.70

Undervalued EV/EBITDA

-14.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

25.78

Current PS

30.71

Overvalued PS

48.28

Undervalued PS

3.28

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 3690.48% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VIR News & Events

Events Timeline

No data

News

7.5

2025-12-17Yahoo Finance

Norgine Expands Hepatology and Specialty Offerings with Exclusive Licensing Deal with Vir Biotechnology

7.5

2025-12-16Newsfilter

Vir Biotechnology Partners with Norgine, Secures €55 Million Initial Payment

9.0

2025-11-09Newsfilter

Vir Biotechnology Reveals Phase 2 Data at AASLD The Liver Meeting® and in NEJM, Showing High Undetectable HDV RNA Rates and Positive Safety Profile for Tobevibart and Elebsiran Combination

People Also Watch

Frequently Asked Questions

What is Vir Biotechnology Inc (VIR) stock price today?

The current price of VIR is 5.85 USD — it has decreased -1.68 % in the last trading day.

What is Vir Biotechnology Inc (VIR)'s business?

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.

What is the price predicton of VIR Stock?

What is Vir Biotechnology Inc (VIR)'s revenue for the last quarter?

Vir Biotechnology Inc revenue for the last quarter amounts to 240.00K USD, decreased -89.92 % YoY.

What is Vir Biotechnology Inc (VIR)'s earnings per share (EPS) for the last quarter?

Vir Biotechnology Inc. EPS for the last quarter amounts to -1.17 USD, decreased -25.00 % YoY.

What changes have occurred in the market's expectations for Vir Biotechnology Inc (VIR)'s fundamentals?

How many employees does Vir Biotechnology Inc (VIR). have?

Vir Biotechnology Inc (VIR) has 408 emplpoyees as of January 10 2026.

What is Vir Biotechnology Inc (VIR) market cap?

Today VIR has the market capitalization of 813.88M USD.